Search

Displaying results 3241 - 3250 of 9322 in total
  1. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

  2. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  3. Drug

    Dapiprazole

    go.drugbank.com/drugs/DB00298
    Approved

    It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.

  4. Drug

    Palivizumab

    go.drugbank.com/drugs/DB00110
    ApprovedInvestigational

    The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. … The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2).

  5. Drug

    Interferon alfa-n3

    go.drugbank.com/drugs/DB00018
    Approved

    Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).

  6. Drug

    Benzoin resin

    go.drugbank.com/drugs/DB11222
    Approved

    Benzoin resin is a balsamic resin obtained from the bark of several species of trees in the genus _Styrax_. … Tincture of benzoin solution is a topical adhesive agent used to provide tackiness and enhance the adhesive property of tape.

    Mixtures: Skin-E-dip Ont
  7. Drug

    Remikiren

    go.drugbank.com/drugs/DB00212
    Experimental

    Remikiren is an orally active, high specificity renin inhibitor.

    Categories: Agents Acting on the Renin-Angiotensin System
  8. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.

  9. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission. … Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.

  10. Drug

    Calcium glycerophosphate

    go.drugbank.com/drugs/DB11264
    Approved

    It is also present in dental or oral hygiene products due to its cariostatic effects. … The commercial product is a mixture of calcium beta-, and D-, and L -alpha-glycerophosphate.